LabConnect Partners with The Bracken Group to Boost Radiopharma Support

LabConnect, a leading provider of global central laboratory and support services for clinical trials, announces a strategic collaboration with The Bracken Group to enhance its radiopharmaceutical support capabilities.

As demand for radiopharmaceutical expertise continues to surge, with industry growth estimated between 15% and 20% annually, this collaboration positions LabConnect to better serve biotech and pharmaceutical clients advancing targeted treatments and diagnostics.

"This partnership creates a unique opportunity to integrate operational excellence with deep scientific acumen," said Wes Wheeler, CEO at LabConnect. "Bracken's expertise strengthens our ability to support global clients with the complex logistical and analytical challenges specific to radiopharmaceutical trials."

"LabConnect's commitment to innovation aligns with Bracken's mission," said Colin Miller, PhD, CEO at Bracken Consulting. "Together, we're creating a bridge between medicine, science, and operations that is unmatched in our industry." He went on to say "Bracken is the global leader in consulting for radiopharmaceutical development from pre-clinical to market strategy. In partnering with LabConnect we have the opportunity to further build out the expertise aligning LabConnect as the go to partner organization for their clients developing radiopharmaceuticals, both diagnostics and radiolabeled therapy (RLT)."

The collaboration will focus on enhanced service delivery in areas such as sample processing, logistics, and scientific oversight—all critical components in the complex and highly regulated radiopharmaceutical field.